Recent Investment Analysts’ Ratings Changes for Vericel (VCEL)

Several analysts have recently updated their ratings and price targets for Vericel (NASDAQ: VCEL):

• 7/31/2026 – Vericel was upgraded by Weiss Ratings from “sell (d+)” to “hold (c)”.
• 7/31/2026 – Vericel had its price target raised by TD Cowen from $55.00 to $58.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Vericel had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $58.00 price target on the stock, up from $54.00.
• 7/30/2026 – Vericel was given a new $60.00 price target by Canaccord Genuity Group Inc..
• 7/28/2026 – Vericel had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 7/18/2026 – Vericel was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – Vericel had its price target raised by Truist Financial Corporation from $42.00 to $54.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Vericel was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 6/14/2026 – Vericel was downgraded by Wall Street Zen from “buy” to “hold”.

Insiders Place Their Bets

In other news, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $44.75, for a total transaction of $223,750.00. Following the transaction, the chief financial officer directly owned 16,009 shares in the company, valued at $716,402.75. This represents a 23.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 75,753 shares in the company, valued at approximately $3,408,885. This trade represents a 11.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 52,232 shares of company stock valued at $2,304,217 in the last quarter. Corporate insiders own 7.60% of the company’s stock.

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.